Last reviewed · How we verify
Dimethindene — Competitive Intelligence Brief
phase 1
dimetindene
Histamine H1 receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Dimethindene (dimetindene) — Margitta Worm. Dimethindene works by blocking the histamine H1 receptor, which is involved in allergic reactions and other histamine-related processes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dimethindene TARGET | dimetindene | Margitta Worm | phase 1 | dimetindene | Histamine H1 receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (dimetindene class)
- Margitta Worm · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dimethindene CI watch — RSS
- Dimethindene CI watch — Atom
- Dimethindene CI watch — JSON
- Dimethindene alone — RSS
- Whole dimetindene class — RSS
Cite this brief
Drug Landscape (2026). Dimethindene — Competitive Intelligence Brief. https://druglandscape.com/ci/dimetindene. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing